soul trial oral semaglutide trial: 14 mg demonstrated superior reduction in risk of CV events Oral GLP-1 receptor agonist Rybelsus

FDA Submission Timeline Based on the TRIUMPH-4 success and expected 2026 readouts, analysts predict: Late 2026: Completion of core TRIUMPH trials Q4 2026 or Q1 2027: New Drug Application (NDA) submission to FDA Mid to Late 2027: Potential FDA approval Early 2028: Commercial launch Eli Lilly has not officially confirmed these timelines, but the company has indicated it will submit for regulatory approval once sufficient Phase 3 data is available

Even patients with obesity-related comorbidities like hypertension or sleep apnea often receive denials when requesting Wegovy coverage through their plans

The advantages of precision dosing through microdosing are multifaceted

Only a minority of participants chose to discontinue treatment because of hypersensitivity, and discontinuation rates for these reactions were not significantly higher than those observed with placebo groups